<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105988">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027662</url>
  </required_header>
  <id_info>
    <org_study_id>RP-OSV-02-D</org_study_id>
    <nct_id>NCT02027662</nct_id>
  </id_info>
  <brief_title>Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules</brief_title>
  <acronym>OsvaRen-NEW</acronym>
  <official_title>Study to Investigate Efficacy and Safety Equivalence of OsvaRen® Tablets and OsvaRen® Granules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phosphate binders are crucial to the control of elevated phosphate levels in patients with
      chronic kidney disease. With the new formulation of granules the pill burden of patients is
      sought to be reduced.

      This study is about efficacy and safety of the new drug formulation and compares it to the
      &quot;old&quot; formulation which are film-coated tablets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is aimed at demonstrating the therapeutic equivalence of both products, i.e.
      granules versus tablets.

      Secondary objectives are: Comparing both preparations with regard to the number of patients
      reaching serum phosphate levels &lt; 1.76 mmol/L and the difference in serum phosphate levels
      between the first and last visit under each treatment. Furthermore, it is the aim of this
      study to evaluate the safety profile of OsvaRen® granules in comparison to OsvaRen® tablets.
      Especially serum calcium, magnesium, and PTH are of interest.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Non-inferiority of phosphate control by granules versus tablets. Serum phosphate levels will be measured for the primary outcome.</measure>
    <time_frame>After 4 weeks of treatment time</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients reaching serum phosphate levels &lt; 1.76 mmol/L. this study to evaluate the safety profile of OsvaRen® granules. in comparison to OsvaRen® tablets. Especially serum calcium, magnesium, and PTH are of interest.</measure>
    <time_frame>Between the first and last visit under each treatment i.e. 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Osvaren Granules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osvaren Granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osvaren film-coated tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Osvaren film-coated tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osvaren Granules</intervention_name>
    <arm_group_label>Osvaren Granules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osvaren film-coated tablets</intervention_name>
    <arm_group_label>Osvaren film-coated tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent form is obtained prior to starting the screening
             visit

          -  Male and female patients 18-80 years of age with dialysis dependent renal failure
             (CKD 5D)

          -  Patients have been on 3x/week in-centre renal replacement therapy for at least 2
             months on either low-flux or high-flux HD or OL-

             /HDF

          -  Prescribed haemodialysis session duration is ≥ 4 hours

          -  spKt/V ≥ 1.20 according to last in-centre measurement prior the study enrolment

          -  Patients have been on OsvaRen® tablets for at least 12 weeks as sole phosphate binder
             and the titration phase has been completed according to physician´s discretion

          -  Patients are able to take the study medication as prescribed particularly OsvaRen®
             stickpacks

          -  Patients are willing to stop any calcium, magnesium or vitamin D containing
             supplements

          -  Patients are willing to maintain their typical diet with regards to phosphate uptake
             for the time of the study

          -  Patients are willing to comply with the study protocol

        Exclusion criteria

          -  Pregnant women (by blood ß-hCG pregnancy test) or women breast-feeding or unwilling
             to use contraceptive measures during the entire course of the study or

          -  Patients with a life expectancy shorter than the planned duration of the study or

          -  Patients with any acute or chronic severe disease potentially interfering with study
             outcomes or

          -  Patients with PTH levels &gt; 800 ng/l or

          -  Patients who participated in an interventional clinical study during the preceding 30
             days or

          -  Patients suffering from any other, not mentioned condition which could interfere with
             the patient's ability to comply with the study or

          -  Patients who previously participated in the same study are excluded from the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Floege, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Aachen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank M Laukhuf, MD</last_name>
    <phone>+496172609</phone>
    <phone_ext>4172</phone_ext>
    <email>frank.laukhuf@fmc.ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Schulz, PhD</last_name>
    <phone>+496172609</phone>
    <phone_ext>5457</phone_ext>
    <email>thomas.schulz@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RWTH University Hospital, Dpt for Nephrology</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Floege, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Michael Moeller, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jürgen Floege, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephro-Studien GbR am Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Haufe, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ines Solf, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Christoph Haufe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Ries, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephan Schmiedel, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang Ries, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrocare Hamburg-Barmbek GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22297</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Toussaint, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Rolf Schneidenbach, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Kai Toussaint, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Schmidt-Gürtler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Wanja Bernhardt, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hans Schmidt-Gürtler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Kiel</city>
        <zip>24106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekkehardd Ziegler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tilman David-Walek, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ekkehard Ziegler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ute Domröse, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Matthias Nielebock, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ute Domröse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Radermacher, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ulrich Schmitz, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jörg Radermacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Solingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schmitz, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Hans Heering, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Schmitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Velbert</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Koch, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sendokan Aker, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>December 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
